Izencitinib
As of the edition of 20 October 2026, Izencitinib is a small molecule: stopped in 2021; acts on JAK1, JAK2 and JAK3 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Small molecule
- Registered trials
- 8, 2 stopped early
- Disease areas
- Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 |
| Phase 3 | 2 | 0 | 0 | 2 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Theravance Biopharma | Lead sponsor of trials | 2015 to now |